← Back to Search

Cancer Screening for Lung Cancer

N/A
Waitlist Available
Led By Christine D Berg
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.
Awards & highlights

Summary

This trial is testing whether screening for various types of cancer can reduce deaths from those cancers.

Who is the study for?
This trial is for older individuals who may be at risk of lung cancer. Participants will undergo screening methods to detect any signs of cancer early on, which could lead to better treatment outcomes.
What is being tested?
The study is testing the effectiveness of a screening questionnaire and X-ray imaging in identifying lung cancer in its early stages, with the goal of reducing mortality from this disease.
What are the potential side effects?
There are generally minimal side effects associated with completing a screening questionnaire and undergoing X-ray imaging. However, there might be some discomfort or anxiety related to the procedures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Lung Cancer Death Rates
Lung Cancer Deaths
Secondary study objectives
Complications of Diagnostic Evaluation Following a Positive Screening Test
Death Rates From All Causes
Deaths From All Causes
+6 more

Trial Design

2Treatment groups
Active Control
Group I: Lung ScreeningActive Control2 Interventions
Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.
Group II: ControlActive Control1 Intervention
Participants receive standard medical care. Participants complete a DHQ at baseline.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,842 Previous Clinical Trials
40,848,099 Total Patients Enrolled
Christine D BergPrincipal InvestigatorNational Cancer Institute (NCI)
3 Previous Clinical Trials
309,801 Total Patients Enrolled

Media Library

X-Ray Imaging Clinical Trial Eligibility Overview. Trial Name: NCT01696968 — N/A
Lung Cancer Research Study Groups: Lung Screening, Control
Lung Cancer Clinical Trial 2023: X-Ray Imaging Highlights & Side Effects. Trial Name: NCT01696968 — N/A
X-Ray Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT01696968 — N/A
~4866 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top